News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
638,883 Results
Type
Article (55517)
Company Profile (218)
Press Release (583148)
Multimedia
Podcasts (104)
Webinars (13)
Section
Business (174844)
Career Advice (2496)
Deals (32131)
Drug Delivery (128)
Drug Development (81374)
Employer Resources (155)
FDA (16835)
Job Trends (13749)
News (314631)
Policy (34063)
Tag
2025 Lone Star Bio Digital (3)
Academia (2687)
Academic (1)
Accelerated approval (6)
Adcomms (29)
Allergies (88)
Alliances (45942)
ALS (97)
Alzheimer's disease (1500)
Antibody-drug conjugate (ADC) (156)
Approvals (16801)
Artificial intelligence (276)
Autoimmune disease (28)
Automation (13)
Bankruptcy (327)
Best Places to Work (10432)
BIOSECURE Act (22)
Biosimilars (117)
Biotechnology (155)
Bladder cancer (80)
Brain cancer (32)
Breast cancer (291)
Cancer (2336)
Cardiovascular disease (195)
Career advice (2095)
Career pathing (34)
CAR-T (156)
Cell therapy (443)
Cervical cancer (19)
Clinical research (65955)
Collaboration (861)
Compensation (529)
Complete response letters (30)
COVID-19 (2724)
CRISPR (48)
C-suite (249)
Cystic fibrosis (103)
Data (2182)
Decentralized trials (2)
Denatured (29)
Depression (53)
Diabetes (286)
Diagnostics (5794)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (42)
Drug discovery (138)
Drug pricing (127)
Drug shortages (33)
Duchenne muscular dystrophy (100)
Earnings (67430)
Editorial (44)
Employer branding (20)
Employer resources (139)
Events (95121)
Executive appointments (712)
FDA (18122)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (749)
Gene editing (114)
Generative AI (25)
Gene therapy (342)
GLP-1 (837)
Government (4288)
Grass and pollen (6)
Guidances (56)
Healthcare (16965)
Huntington's disease (25)
IgA nephropathy (31)
Immunology and inflammation (145)
Indications (30)
Infectious disease (2877)
Inflammatory bowel disease (141)
Inflation Reduction Act (11)
Influenza (52)
Intellectual property (98)
Interviews (455)
IPO (15459)
IRA (51)
Job creations (3737)
Job search strategy (1748)
Kidney cancer (11)
Labor market (32)
Layoffs (534)
Leadership (24)
Legal (8140)
Liver cancer (77)
Lung cancer (336)
Lymphoma (156)
Machine learning (7)
Management (54)
Manufacturing (327)
MASH (73)
Medical device (12058)
Medtech (12062)
Mergers & acquisitions (17222)
Metabolic disorders (762)
Multiple sclerosis (86)
NASH (23)
Neurodegenerative disease (110)
Neuropsychiatric disorders (34)
Neuroscience (2091)
NextGen: Class of 2025 (5779)
Non-profit (4301)
Northern California (2609)
Now hiring (25)
Obesity (416)
Opinion (269)
Ovarian cancer (71)
Pain (91)
Pancreatic cancer (82)
Parkinson's disease (159)
Partnered (18)
Patents (241)
Patient recruitment (104)
Peanut (48)
People (51927)
Pharmaceutical (46)
Pharmacy benefit managers (21)
Phase I (20272)
Phase II (28686)
Phase III (22112)
Pipeline (1215)
Policy (170)
Postmarket research (2918)
Preclinical (8674)
Press Release (61)
Prostate cancer (112)
Psychedelics (37)
Radiopharmaceuticals (258)
Rare diseases (420)
Real estate (5254)
Recruiting (61)
Regulatory (23885)
Reports (33)
Research institute (2419)
Resumes & cover letters (408)
Rett syndrome (4)
RNA editing (4)
RSV (48)
Schizophrenia (80)
Series A (135)
Series B (87)
Service/supplier (12)
Sickle cell disease (58)
Southern California (2221)
Special edition (16)
Spinal muscular atrophy (163)
Sponsored (34)
Startups (3399)
State (1)
Stomach cancer (16)
Supply chain (73)
Tariffs (45)
The Weekly (73)
United States (22410)
Vaccines (785)
Venture capitalists (44)
Weight loss (300)
Women's health (33)
Worklife (20)
Date
Today (161)
Last 7 days (852)
Last 30 days (2654)
Last 365 days (32702)
2025 (10768)
2024 (34725)
2023 (38973)
2022 (49766)
2021 (53530)
2020 (51064)
2019 (42162)
2018 (32109)
2017 (31980)
2016 (30679)
2015 (34508)
2014 (27586)
2013 (23027)
2012 (24681)
2011 (25421)
2010 (23665)
Location
Africa (842)
Alabama (56)
Alaska (6)
Arizona (184)
Arkansas (12)
Asia (39369)
Australia (6738)
California (5927)
Canada (1795)
China (527)
Colorado (248)
Connecticut (287)
Delaware (151)
Europe (90492)
Florida (892)
Georgia (190)
Hawaii (1)
Idaho (45)
Illinois (507)
India (28)
Indiana (284)
Iowa (11)
Japan (162)
Kansas (97)
Kentucky (23)
Louisiana (10)
Maine (64)
Maryland (902)
Massachusetts (4511)
Michigan (195)
Minnesota (365)
Mississippi (1)
Missouri (89)
Montana (24)
Nebraska (24)
Nevada (57)
New Hampshire (58)
New Jersey (1715)
New Mexico (27)
New York (1672)
North Carolina (995)
North Dakota (7)
Northern California (2609)
Ohio (189)
Oklahoma (11)
Oregon (33)
Pennsylvania (1296)
Puerto Rico (13)
Rhode Island (29)
South America (1191)
South Carolina (22)
South Dakota (1)
Southern California (2221)
Tennessee (88)
Texas (862)
Utah (159)
Virginia (144)
Washington D.C. (61)
Washington State (538)
West Virginia (3)
Wisconsin (57)
638,883 Results for "alzheimer s drug discovery foundation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of potentially fatal brain swelling and bleeding.
March 28, 2025
·
2 min read
·
Dan Samorodnitsky
Deals
Coya Therapeutics Announces $5 Million Strategic Investment by the Alzheimer’s Drug Discovery Foundation (ADDF)
Coya Therapeutics, Inc. announces that the Alzheimer’s Drug Discovery Foundation (“ADDF”) has purchased 603,136 shares of the Company’s common stock at a purchase price of $8.29 per share for an aggregate investment of $5 million.
May 20, 2024
·
14 min read
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Cassava Finally Ends Alzheimer’s Program for Embattled Simufilam
After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.
March 25, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease
January 8, 2025
·
5 min read
Press Releases
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug
April 29, 2025
·
3 min read
Collaboration
Cassava’s Stock Rises After Licensing Seizure Rights for Embattled Drug Simufilam
The licensing deal follows years of controversy for Cassava, as well as the high-profile late-stage failure of its Alzheimer’s disease drug simufilam.
February 28, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Porosome Therapeutics Unveils Groundbreaking Discovery in Alzheimer’s Disease Research and Treatment
March 25, 2025
·
5 min read
Deals
Genentech Offers up to $765M in Biobucks to Repertoire for I&I Drug Discovery
Roche’s Genentech is betting on the Flagship Pioneering–founded company’s discovery platform called DECODE to find new targets for an undisclosed autoimmune disorder.
April 23, 2025
·
1 min read
·
Dan Samorodnitsky
BioMidwest
Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Center for Brain Health Medicines Invite Proposals for 2024 ADDF-Harrington Scholar Award
Harrington Discovery Institute Center for Brain Health Medicines at University Hospitals and the Alzheimer’s Drug Discovery Foundation announce a joint request for proposals for the 2024 ADDF-Harrington Scholar Award.
April 1, 2024
·
4 min read
1 of 63,889
Next
